Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method of improving killing effect of CIK cells on cancer cells

A cancer cell, cell technology, applied in the medical field, can solve the problems of limited number of cells, short cell culture time, difficult to meet clinical treatment, etc., to achieve the effect of promoting killing activity and increasing the ratio of effective targets

Inactive Publication Date: 2013-12-25
合肥凤凰肿瘤医院
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The activation technology of CIK cells usually uses CD3 monoclonal antibody, interleukin-1, interleukin-2 and interferon INF-γ for activation and expansion. The effect of cell expansion is not satisfactory, and many units want to reduce the cost of culture The cell culture time is short, and the culture time of individual reports is only 2-3 days, so the number of cells obtained is limited, and the proportion of effective targets (CIK: cancer cells) is low, which is difficult to meet the needs of clinical treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of improving killing effect of CIK cells on cancer cells
  • Method of improving killing effect of CIK cells on cancer cells
  • Method of improving killing effect of CIK cells on cancer cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The method for improving the killing effect of CIK cells on cancer cells specifically includes the following steps:

[0029] In the process of CIK cell induction, CD3 monoclonal antibody, interleukin-1, interleukin-2, interferon IFN-γ and interleukin-24 were added.

[0030] In the method for improving the killing effect of CIK cells on cancer cells provided by the present invention, the CD3 monoclonal antibody and IFN-γ are required for each plan, and the CD3 monoclonal antibody plays a role of mitogen activity and can be combined with T CD3 cross-linking on the cell surface induces its activation; interferon IFN-γ can induce the synthesis of factors such as interleukin-1. The main difference between the different schemes is the difference in interleukins. At present, researchers are committed to improving the activity of CIK to kill tumor cells. Some of them add interleukin-7 or interleukin-12 or interleukin-15, etc., and there are also applications Reports of genetic modi...

Embodiment 2

[0035] Based on the above embodiments, the present invention also makes the following improvements:

[0036] In the process of CIK cell induction, when adding CD3 monoclonal antibody, interleukin-1, interleukin-2, and interferon INF-γ, add them in the following order:

[0037] Add CD3 monoclonal antibody to CIK cells;

[0038] Add interferon IFN-γ and interleukin-24;

[0039] After 24 hours, add interleukin-1 and interleukin-2.

[0040] Among them, after the step of adding interleukin-1 and interleukin-2 after 24 hours, it also includes:

[0041] For each passage and expansion, interleukin-2, interferon INF-γ and interleukin-24 are supplemented again.

[0042] The passage includes at least 5 times.

[0043] Among them, the amount of interleukin-24 added is based on the amount of CIK cells. In order to improve the induction effect, it is necessary to maintain the concentration of interleukin-24 added in the culture medium at 1000IU / mL, usually the concentration of CIK cells Keep at 10 6 IU...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medical treatment, in particular to a method of improving the killing effect of CIK cells on cancer cells. The method of improving the killing effect of the CIK cells on the cancer cells specifically comprises the following steps: in the process of inducing the CIK cells, a CD3 monoclonal antibody, interleukin-1, interleukin-2, interferon IFN-gamma and interleukin-24 are added. By means of the method of improving the killing effect of the CIK cells on the cancer cells, the effect-target ratio is increased, and the killing activity to tumor cells is promoted.

Description

Technical field [0001] The present invention relates to the medical field, in particular to a method for improving the killing effect of CIK cells on cancer cells. Background technique [0002] Cytokine-induced killer cells (CIK cells) are a group of heterogeneous cells obtained by co-inducing human peripheral blood mononuclear cells with multiple cytokines in vitro. A large number of studies have shown that CIK cells are a new type of non-major histocompatibility complex (MHC) restricted immune effector cells with high-efficiency and broad-spectrum tumor-killing activity. They have shown great application value in tumor immunotherapy and have comparative advantages. LAK, CTL, TIL have stronger proliferation ability and cytotoxicity, and have no MHC restriction, so they have become the research hotspot of tumor biotherapy in the past decade. [0003] The activation technology of CIK cells usually uses CD3 monoclonal antibody, interleukin-1, interleukin-2 and interferon INF-γ for a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/078
Inventor 王志华
Owner 合肥凤凰肿瘤医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com